These Analysts Revise Their Forecasts On Arvinas After Q4 Results
1. Arvinas reported quarterly losses of 63 cents per share, better than expected. 2. Sales missed estimates at $59.20 million vs. $65.28 million forecast. 3. Future clinical trial VERITAC-2 expected to drive innovations in treatment. 4. Analyst price target revisions reflect mixed outlook on stock performance. 5. ARVN shares showed a slight increase after earnings announcement.